Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;34(1):52-8.
doi: 10.3857/roj.2016.34.1.52. Epub 2016 Mar 30.

FXYD-3 expression in relation to local recurrence of rectal cancer

Per Loftas  1 , Gunnar Arbman  1 , Xiao-Feng Sun  2 , David Edler  3 , Erik Syk  4 , Olof Hallbook  5
Affiliations

FXYD-3 expression in relation to local recurrence of rectal cancer

Per Loftas et al. Radiat Oncol J. 2016 Mar.

Abstract

Purpose: In a previous study, the transmembrane protein FXYD-3 was suggested as a biomarker for a lower survival rate and reduced radiosensitivity in rectal cancer patients receiving preoperative radiotherapy. The purpose of preoperative irradiation in rectal cancer is to reduce local recurrence. The aim of this study was to investigate the potential role of FXYD-3 as a biomarker for increased risk for local recurrence of rectal cancer.

Materials and methods: FXYD-3 expression was immunohistochemically examined in surgical specimens from a cohort of patients with rectal cancer who developed local recurrence (n = 48). The cohort was compared to a matched control group without recurrence (n = 81).

Results: Weak FXYD-3 expression was found in 106/129 (82%) of the rectal tumors and strong expression in 23/129 (18%). There was no difference in the expression of FXYD-3 between the patients with local recurrence and the control group. Furthermore there was no difference in FXYD-3 expression and time to diagnosis of local recurrence between patients who received preoperative radiotherapy and those without.

Conclusion: Previous findings indicated that FXYD-3 expression may be used as a marker of decreased sensitivity to radiotherapy or even overall survival. We were unable to confirm this in a cohort of rectal cancer patients who developed local recurrence.

Keywords: Human FXYD3 protein; Local recurrence; Rectal cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Immunohistochemistry showing FXYD-3 expression in the primary tumor (H&E, 10× magnification). (A) Weak FXYD-3 expression in the primary tumor. (B) Strong FXYD-3 expression in the primary tumor.
Fig. 2
Fig. 2. Time to local recurrence in all 129 patients. Weak FXYD-3 expression (grades 0 + 1 + 2, n = 106) vs. strong (grade 3, n = 23).
See this image and copyright information in PMC

References

    1. Dahlberg M, Pahlman L, Bergstrom R, Glimelius B. Improved survival in patients with rectal cancer: a population-based register study. Br J Surg. 1998;85:515–520. - PubMed
    1. Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol. 2003;42:476–492. - PubMed
    1. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–646. - PubMed
    1. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B Swedish Rectal Cancer Trial Group. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005;23:8697–8705. - PubMed
    1. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol. 2005;23:6126–6131. - PubMed